top of page
Browse by category
Search
No significant differences between LigaSure and Harmonic in LSG outcomes
There are no significant differences between LigaSure (Medtronic) and Harmonic (Ethicon Endo-Surgery) devices in terms of operative time,...
Endoscopic BariTon™ implant intended to mimic sleeve gastrectomy and bypass surgery
In February 2024, BariaTek Medical announced that it had successfully performed the first-in-human implant of the BariTon™, an...
US researchers to assess the impact of physical activity after bariatric surgery
A research team at the Hartford HealthCare Digestive Health Institute (DHI) will launch a new study, funded by a US$2.9-million federal...
GLP-1RAs may lead to increased risk of aspiration pneumonia following endoscopy
People who are scheduled for certain medical procedures should stop taking glucagon-like peptide-1 receptor agonists (GLP-1RAs)...
Bariatric surgery alleviates electrocardiographic abnormalities
Bariatric surgeries can correct abnormal R wave progression and resolve QT dispersion in morbidly obese patients, according to...
Innovative program connects bariatric surgery and kidney transplant access for patients who have obesity and end-stage renal disease
A collaborative study between bariatric and transplant teams has created a viable pathway for patients with obesity who also have...
GLP-1 RA linked to increased residual gastric content before anaesthesia
Safety concerns for patients undergoing anaesthesia who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been revealed in a...
SASI bypass and OAGB more effective than SG in the treatment of metabolic syndrome
A retrospective analysis of sleeve gastrectomy (SG), one-anastomotic gastric bypass (OAGB) and single anastomosis sleeve ileal (SASI)...
AMOS2: Surgery does not improve executive function or memory in adolescents vs. intensive non-surgical treatment
Bariatric surgery, which was associated with significant weight loss, was overall no more effective than intensive non-surgical...
FLOW trial: Semaglutide 1.0mg demonstrates 24% reduction in the risk of kidney disease-related events in T2DM and chronic kidney disease patients
Headline results from the kidney outcomes trial FLOW (Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in...
Browse by tag
bottom of page